Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03817684 · ClinicalTrials.gov registry record · Phase 2
Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects
A Phase 2 study, sponsored by Tetra Discovery Partners.
- Completed
- Registry status
- Phase 2
- Development phase
- 255
- Enrollment target
NCT03817684: Completed Phase 2 study, sponsored by Tetra Discovery Partners.
NCT03817684 is a Phase 2 study that has completed, run by Tetra Discovery Partners. The registered enrollment target is 255 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03817684, a Phase 2 study, has completed, sponsored by Tetra Discovery Partners.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 255 participants
- Enrollment target
Study Summary
A Randomized, Double-blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients with Early Alzheimer's Disease
Interventions
- DRUG Placebo
- DRUG BPN14770
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2020-02-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03817684
The ClinicalTrials.gov registry entry for NCT03817684 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tetra Discovery Partners, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03817684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03817684 about?
NCT03817684 is a clinical study titled "Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects". A Randomized, Double-blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients with Early Alzheimer's Disease
What is the current status of trial NCT03817684?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2019-04-30. Estimated completion is 2020-02-04.
What interventions are being tested in trial NCT03817684?
The interventions under investigation include: Placebo (DRUG), BPN14770 (DRUG).
Who is sponsoring clinical trial NCT03817684?
This trial is sponsored by Tetra Discovery Partners, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.